Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

GALT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Galectin Therapeutics Inc.NASDAQ: GALT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 65.78M shares rose 4.1% year over year, ahead of the +2.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.1% holds above the trailing-twelve-month pace of +2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
65.78M+2.9% QoQ
Last fiscal yearDec 2025
63.9M+2.6% YoY
LTMMar 2026
64.33M+2.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.1%——
1 year+2.6%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
63.9M USD
Year-over-year change
+2.6%
4-year CAGR
+2.2%

Weighted Avg Shares (Diluted) vs competitors

How GALT compares with its peers on the latest reported figures

  • GALT's LTM Mar 2026 weighted avg shares (diluted) of 64.33M shares is the 5th highest of the 10 companies compared; the peer median is 62.93M shares.
  • Its year-over-year change of +2.7% is the 8th highest of 9, against a peer median of +23.4%.
  • Over three fiscal years its annual growth of +2.5% compares with a peer median of +21.1%.
GALT Competitors Peer median
Weighted Avg Shares (Diluted) for GALT and competitors
Company Period LTM YoY 3-year CAGR
QSIQuantum-Si incorporatedLTM Mar 2026201.73M +31.6%+12.4%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 202685.25M +21.6%+8.2%
GALTGalectin Therapeutics Inc.LTM Mar 202664.33M +2.7%+2.5%
AURAAura Biosciences, Inc.LTM Mar 202662.93M +26.5%+26.3%
ENGNenGene Holdings Inc.LTM Apr 202659.85M +25.2%+47.9%
DSGNDesign Therapeutics, Inc.LTM Mar 202658.14M +2.6%+1.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
Peer median (excluding GALT) 62.93M+23.4%+21.1%

Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.82M31.74M32.13M36.57M14.29M
Selling, General & Admin6.36M6.62M5.94M5.86M5.8M
Operating Expenses30.18M38.35M38.07M42.43M20.09M
Depreciation & Amortization41K32K33K37K53K
EBITDA(30M)(37.71M)(38.24M)(41.47M)(23.45M)
EBITDA Margin—————
Operating Income(30.18M)(38.35M)(38.07M)(42.43M)(20.09M)
Operating Margin—————
Interest Income3K52K230K338K126K
Interest Expense489K1.03M2.79M5.54M7.33M
Other Income / Expenses(348K)(424K)(2.99M)(4.61M)(10.75M)
Income Before Tax(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Net Margin—————
EPS (Basic)(0.52)(0.65)(0.74)(0.76)(0.48)
EPS (Diluted)(0.52)(0.65)(0.74)(0.76)(0.48)
Weighted Avg Shares58.53M59.39M60.16M62.31M63.9M
Weighted Avg Shares (Diluted)58.53M59.39M60.16M62.31M63.9M

Galectin Therapeutics Inc.

NASDAQ:GALT

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.